Cells (Mar 2023)

Reduced Levels of Misfolded and Aggregated Mutant p53 by Proteostatic Activation

  • Evelyne Naus,
  • Marleen Derweduwe,
  • Youlia Lampi,
  • Annelies Claeys,
  • Jarne Pauwels,
  • Tobias Langenberg,
  • Filip Claes,
  • Jie Xu,
  • Veerle Haemels,
  • Zeynep Kalender Atak,
  • Rob van der Kant,
  • Joost Van Durme,
  • Greet De Baets,
  • Keith L. Ligon,
  • Mark Fiers,
  • Kris Gevaert,
  • Stein Aerts,
  • Frederic Rousseau,
  • Joost Schymkowitz,
  • Frederik De Smet

DOI
https://doi.org/10.3390/cells12060960
Journal volume & issue
Vol. 12, no. 6
p. 960

Abstract

Read online

In malignant cancer, excessive amounts of mutant p53 often lead to its aggregation, a feature that was recently identified as druggable. Here, we describe that induction of a heat shock-related stress response mediated by Foldlin, a small-molecule tool compound, reduces the protein levels of misfolded/aggregated mutant p53, while contact mutants or wild-type p53 remain largely unaffected. Foldlin also prevented the formation of stress-induced p53 nuclear inclusion bodies. Despite our inability to identify a specific molecular target, Foldlin also reduced protein levels of aggregating SOD1 variants. Finally, by screening a library of 778 FDA-approved compounds for their ability to reduce misfolded mutant p53, we identified the proteasome inhibitor Bortezomib with similar cellular effects as Foldlin. Overall, the induction of a cellular heat shock response seems to be an effective strategy to deal with pathological protein aggregation. It remains to be seen however, how this strategy can be translated to a clinical setting.

Keywords